These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Small heterodimer partner (SHP) aggravates ER stress in Parkinson's disease-linked LRRK2 mutant astrocyte by regulating XBP1 SUMOylation. Lee JH; Han JH; Joe EH; Jou I J Biomed Sci; 2021 Jul; 28(1):51. PubMed ID: 34229656 [TBL] [Abstract][Full Text] [Related]
24. LRRK2 interferes with aggresome formation for autophagic clearance. Bang Y; Kim KS; Seol W; Choi HJ Mol Cell Neurosci; 2016 Sep; 75():71-80. PubMed ID: 27364102 [TBL] [Abstract][Full Text] [Related]
25. Developmental neurotoxicity of reserpine exposure in zebrafish larvae (Danio rerio). Wang S; Duan M; Guan K; Zhou X; Zheng M; Shi X; Ye M; Guan W; Kuver A; Huang M; Liu Y; Dai K; Li X Comp Biochem Physiol C Toxicol Pharmacol; 2019 Sep; 223():115-123. PubMed ID: 31128281 [TBL] [Abstract][Full Text] [Related]
26. Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation. Islam MS; Moore DJ Biochem Soc Trans; 2017 Feb; 45(1):163-172. PubMed ID: 28202670 [TBL] [Abstract][Full Text] [Related]
27. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease. Monfrini E; Di Fonzo A Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276 [TBL] [Abstract][Full Text] [Related]
28. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO Elife; 2020 Feb; 9():. PubMed ID: 32057291 [TBL] [Abstract][Full Text] [Related]
29. LRRK2 activation in idiopathic Parkinson's disease. Di Maio R; Hoffman EK; Rocha EM; Keeney MT; Sanders LH; De Miranda BR; Zharikov A; Van Laar A; Stepan AF; Lanz TA; Kofler JK; Burton EA; Alessi DR; Hastings TG; Greenamyre JT Sci Transl Med; 2018 Jul; 10(451):. PubMed ID: 30045977 [TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease. Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718 [TBL] [Abstract][Full Text] [Related]
31. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood. Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796 [TBL] [Abstract][Full Text] [Related]
32. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations. Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L Elife; 2020 Oct; 9():. PubMed ID: 33006315 [TBL] [Abstract][Full Text] [Related]
33. Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio). Anichtchik O; Sallinen V; Peitsaro N; Panula P J Comp Neurol; 2006 Oct; 498(5):593-610. PubMed ID: 16917825 [TBL] [Abstract][Full Text] [Related]
34. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
35. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901 [TBL] [Abstract][Full Text] [Related]
36. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein. Ho DH; Seol W; Son I Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480 [TBL] [Abstract][Full Text] [Related]
37. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function. Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688 [TBL] [Abstract][Full Text] [Related]
39. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161 [TBL] [Abstract][Full Text] [Related]
40. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration. Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]